Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms

Clinical Drug Investigation

Volumn 19, Issue 2, 2000, Pages 83-91

  Chancellor, Michael ^a   Freedman, S ^f   Mitcheson, H D ^b   Antoci, J ^c   Primus, G ^d   Wein, A ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Bay State Urologists Inc   (United States)

^c Urology Specialists   (United States)

^d University Eye Clinic   (Austria)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URGE INCONTINENCE; XEROSTOMIA;

EID: 0034008398     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019020-00001     Document Type: Article

References (30)

1. Jackson S. The patient with overactive bladder - symptoms and quality of life issues. Urology 1997; 50 (6A Suppl.): 18-22
2. Johannesson M, O'Connor RM, Kobelt G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80:557-62
3. Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 583-90
4. Wein AJ, Rovner ES. The overactive bladder: An overview for primary care health providers. Int J Fertil Womens Med 1999; 44: 56-66
5. Andersson K-E. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477-94
6. Andersson K-E. The overactive bladder: Pharmacologic basis of drug treatment. Urology 1997; 50 (6A Suppl.): 74-84
7. Yarker Y, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62
8. Drutz H, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-9
9. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8-13
10. Nilvebrant L, Anderson K-E, Gillberg P-G, et al. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207
11. Nilvebrant L, Hallén B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129-36
12. Stahl MMS, Eckström B, Sparf A, et al. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14: 647-55
13. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50 (6A Suppl.): 90-6
14. Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10
15. Atan A, Konety BR, Erickson JR, et al. Tolterodine for overactive bladder: Time to onset of action, preferred dosage, and 9-month follow-up. Tech Urol 1999; 5: 67-70
16. Wein AJ, Abrams P, Appell R, et al. Tolterodine is effective and well tolerated during long-term use in patients with overactive bladder [abstract]. J Urol 1999; 161 Suppl.: 35
17. Zorzitto ML, Holliday PJ, Jewett MA, et al. Oxybutynin chloride for geriatric urinary dysfunction: A double-blind placebo-controlled study. Age Ageing 1989; 18: 195-200
18. Norton P, Karram M, Wall LL, et al. Randomized, double blind trial of terodiline in the treatment of urge incontinence in women. Obstet Gynecol 1994; 84: 386-91
19. Jonas U, Höfner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: Urodynamic evaluation. World J Urol 1997; 15: 144-51
20. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: A dose-ranging study. Br J Urol 1998; 81: 42-8
21. Van Kerrebroeck PEVA, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17: 499-512
22. Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data. Urology 1999; 53: 990-8
23. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-5
24. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161: 1809-12
25. Meyhoff HH, Gerstenberg TC, Nordling J. Placebo - the drug of choice in female motor urge incontinence? Br J Urol 1983; 55: 34-7
26. Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988; 140: 47-50
27. Thüroff J, Bunke B, Ebner A, et al. Randomized, double-blind, multicentre trial on treatment of frequency, urgency, and incontinence related to detrusor hyperreactivity: Oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-17
28. Abrams P, Larsson G, Chapple C, et al. Factors involved in the success of antimuscarinic treatment. Br J Urol 1999; 83 Suppl. 2: 42-7
29. Frewen W. Role of bladder retraining in the treatment of unstable bladder in the female. Urol Clin North Am 1979; 6: 273-7
30. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93